Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PIKA COVID-19 Vaccine in Healthy Adults
NCT05305300Phase 1Completed
- Sponsor
- LakeShore Biopharma Co., Ltd
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PIKA COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by LakeShore Biopharma Co., Ltd. Primary endpoints: Solicited local adverse events, Solicited systemic adverse events and 4 more. Started Oct 2021; status: completed.
02
Drugs
PIKA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05305300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305300.